Prevention of Contrast-Induced Nephropathy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

1996-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Patients with pre-existing kidney disease are at high risk of acute renal failure when exposed to radio-contrast dyes, for example during a cardiac angiogram.

The investigators hypothesize that an infusion of saline + furosemide + mannitol will reduce rates of contrast-induced nephropathy when compared with saline infusion controls.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Bicarbonate v Saline to Prevent Contrast Nephropathy

NCT00384995

Kidney Failure, Acute Contrast Media

TERMINATED PHASE4

Renoprotective Effects of Fluid Prophylaxis Strategies for Contrast Induced Nephropathy (CIN)

NCT00749827

Contrast Induced Nephropathy

WITHDRAWN PHASE4

Study of Intravenous Amino Acid Infusion to Prevent Contrast Dye Mediated Renal Damage

NCT00313807

Contrast Nephropathy Renal Failure

WITHDRAWN PHASE2

Oral Salt and Water to Prevent Contrast Nephropathy

NCT02084771

Acute Kidney Injury

WITHDRAWN PHASE4

The Use of Sodium Bicarbonate in the Prevention of Contrast Induced Nephropathy

NCT00494637

Contrast Induced Nephropathy

TERMINATED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients with pre-existing kidney disease are at high risk of acute renal failure when exposed to radio-contrast dyes, for example during a cardiac angiogram.

We hypothesize that an infusion of saline + furosemide + mannitol will reduce rates of contrast-induced nephropathy when compared with saline infusion controls.

We define an episode of contrast nephropathy using the conventional often published definition of a 25% relative increase in serum creatinine OR a 44 umol absolute increase in serum creatinine within 48 hours of contrast exposure.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Contrast-induced Nephropathy Acute Renal Failure Chronic Renal Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intervention

Saline hydration + mannitol + furosemide

Group Type EXPERIMENTAL

intravenous saline hydration + mannitol + furosemide

Intervention Type DRUG

500 mls half-normal saline + 25g mannitol + 100 mg furosemide

Controls

Saline hydration without mannitol or furosemide

Group Type PLACEBO_COMPARATOR

intravenous saline hydration

Intervention Type DRUG

500 mls half-normal saline

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

intravenous saline hydration + mannitol + furosemide

500 mls half-normal saline + 25g mannitol + 100 mg furosemide

Intervention Type DRUG

intravenous saline hydration

500 mls half-normal saline

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age \> 21 years
* serum creatinine \> 150 umol/L
* able and willing to provide informed consent

Exclusion Criteria

* known hypersensitivity to contrast, furosemide, or mannitol
* unable to tolerate a fluid load (e.g., acute pulmonary edema)
* ESRD, on dialysis
* previous enrollment in this study or previous contrast administration with the last 2 weeks
* refusal by treating physician

Minimum Eligible Age

21 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No